![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
FDA has approved the NDA for alkylating agent, TEPYLUTE (thiotepa), a ready-to-dilute infusion formulation to treat breast and ovarian cancer.
Lead Product(s): Thiotepa
Therapeutic Area: Oncology Product Name: Tepylute
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2024